(Corrects currency of capital expenditure to dollars after Grifols corrected regulatory filing.)
Grifols SA (GRF) expects to generate annual synergies of $230 million beyond 2015 after its merger with Talecris Biotherapeutics Holdings Corp, the company said in
a presentation filed to regulators today.
Grifols, which holds an investor’s day in Barcelona Oct. 17
and Oct. 18, said total capital expenditure from 2011 to 2015 will be $964 million, while integration costs will be $70 million to 2014, lower than the initial estimate, the company said.
To contact the editor responsible for this story: Emma Ross-Thomas at firstname.lastname@example.org